Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/28/2025

Liver Monitoring in Prolonged Iberogast Use

Baseline Examination and Monitoring Intervals

  • The American College of Gastroenterology recommends determining baseline values of ALT, AST, alkaline phosphatase, total bilirubin, and direct bilirubin before starting long-term Iberogast therapy, and assessing risk factors for liver disease, including alcohol consumption, concomitant medication, and exposure to hepatotoxins 1
  • The European Association for the Study of the Liver suggests monitoring liver values (ALT, AST, alkaline phosphatase, bilirubin) every 3-4 weeks for the first 3 months, as most cases of drug-induced liver injury occur within the first 2-24 weeks 2, 3

Handling Elevated Liver Values

  • The American Association for the Study of Liver Diseases recommends continuing Iberogast with close monitoring and repeating liver values within 1-2 weeks for grade 1 elevations (ALT/AST > normal value up to 3× normal value) 4, 1
  • For grade 2 elevations (ALT/AST >3× to 5× normal value), the European Association for the Study of the Liver suggests temporarily discontinuing Iberogast, repeating liver values within 2-5 days, and reviewing all potentially hepatotoxic medications 4, 1
  • For grade 3 elevations (ALT/AST >5× to 20× normal value or bilirubin ≥2× normal value), the American College of Gastroenterology recommends permanently discontinuing Iberogast, repeating liver values within 2-3 days, and consulting a hepatologist 4, 1

Special Patient Groups

  • The American Association for the Study of Liver Diseases suggests that patients with pre-existing liver disease and elevated baseline values (≥1.5× normal value) should have their liver values repeated within 2-5 days if ALT >2× baseline value or >300 U/L 1
  • The European Association for the Study of the Liver recommends closer monitoring for patients over 40 years with persistent ALT elevations, as they have an increased risk of mortality from liver disease 1

Post-Iberogast Discontinuation Monitoring

  • The American College of Gastroenterology recommends repeating liver values 2-4 weeks after discontinuing Iberogast, and continuing monitoring every 2-4 weeks until complete normalization, with a final check at 12 weeks to confirm sustained normalization 5